Xuanzhu Biopharmaceutical (2575) Stock Overview
Engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
2575 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Xuanzhu Biopharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$33.90 |
| 52 Week High | HK$33.96 |
| 52 Week Low | HK$23.82 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 28.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2575 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | n/a | -2.5% | -0.9% |
| 1Y | n/a | 56.0% | 31.9% |
Return vs Industry: Insufficient data to determine how 2575 performed against the Hong Kong Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how 2575 performed against the Hong Kong Market.
Price Volatility
| 2575 volatility | |
|---|---|
| 2575 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in HK Market | 15.4% |
| 10% least volatile stocks in HK Market | 3.4% |
Stable Share Price: 2575's share price has been volatile over the past 3 months compared to the Hong Kong market.
Volatility Over Time: Insufficient data to determine 2575's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 197 | Jiakui Li | www.xuanzhubio.com |
Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates includes Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. The company also develops KM501, a first-in-class HER2/HER2 bispecific antibody drug conjugate, which is in Phase I clinical trial; KM602, which is in Phase I clinical trial for anti-tumor; XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 inhibitor; and XZP-6924, a ubiquitin-specific protease 1 (USP1) inhibitor.
Xuanzhu Biopharmaceutical Co., Ltd. Fundamentals Summary
| 2575 fundamental statistics | |
|---|---|
| Market cap | HK$17.56b |
| Earnings (TTM) | -HK$606.48m |
| Revenue (TTM) | HK$34.84m |
Is 2575 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2575 income statement (TTM) | |
|---|---|
| Revenue | CN¥31.96m |
| Cost of Revenue | CN¥18.40m |
| Gross Profit | CN¥13.56m |
| Other Expenses | CN¥569.92m |
| Earnings | -CN¥556.36m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.07 |
| Gross Margin | 42.43% |
| Net Profit Margin | -1,740.97% |
| Debt/Equity Ratio | 0% |
How did 2575 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/17 17:21 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xuanzhu Biopharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.